Literature DB >> 16338927

Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells.

Ingeborg Hers1, Matthew Wherlock, Yoshimi Homma, Hitoshi Yagisawa, Jeremy M Tavaré.   

Abstract

Protein kinase B (PKB or Akt) plays an essential role in the actions of insulin, cytokines, and growth factors, although the substrates for PKB that are relevant to many of its actions require identification. In this study, we have reported the identification of p122RhoGAP, a GTPase-activating protein selective for RhoA and rodent homologue of the tumor suppressor deleted in liver cancer (DLC1) as a novel insulin-stimulated phosphoprotein in primary rat adipocytes. We have demonstrated that Ser-322 is phosphorylated upon insulin stimulation of intact cells and that this site is directly phosphorylated in vitro by PKB and ribosomal S6 kinase, members of the AGC (protein kinases A, G, and C) family of insulin-stimulated protein kinases. Furthermore, expression of constitutively active mutants of PKB or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) stimulates Ser-322 phosphorylation in intact cells, demonstrating that activation of the PKB or MEK pathway is sufficient for Ser-322 phosphorylation in vivo. Indeed, in primary adipocytes, insulin-stimulated Ser-322 phosphorylation was almost exclusively regulated by the phosphatidylinositol 3-kinase/PKB pathway, whereas in immortalized cells, insulin-stimulated phosphorylation was predominantly regulated by the MEK/extracellular signal-regulated kinase/ribosomal S6 kinase pathway, with the phosphatidylinositol 3-kinase/PKB pathway playing a minor role. These results demonstrate that p122RhoGAP Ser-322 acts as an integrator of signal transduction in a manner dependent on the cellular context.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338927     DOI: 10.1074/jbc.M511008200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.

Authors:  Yi-Chun Liao; Yi-Ping Shih; Su Hao Lo
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

2.  Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion.

Authors:  Emily H Hall; Abbi E Daugherty; Colin K Choi; Alan F Horwitz; David L Brautigan
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

Review 3.  Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver.

Authors:  Yi-Chun Liao; Su Hao Lo
Journal:  Int J Biochem Cell Biol       Date:  2007-04-20       Impact factor: 5.085

4.  p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling.

Authors:  Yuki Abe; Sang-Oh Yoon; Kazuishi Kubota; Michelle C Mendoza; Steven P Gygi; John Blenis
Journal:  J Biol Chem       Date:  2009-03-30       Impact factor: 5.157

5.  Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Karen Man-Fong Sze; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

6.  Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.

Authors:  Brajendra K Tripathi; Tiera Grant; Xiaolan Qian; Ming Zhou; Philipp Mertins; Dunrui Wang; Alex G Papageorge; Sergey G Tarasov; Kent W Hunter; Steven A Carr; Douglas R Lowy
Journal:  J Cell Biol       Date:  2017-11-07       Impact factor: 10.539

7.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

Review 8.  Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).

Authors:  Drazen B Zimonjic; Nicholas C Popescu
Journal:  Int J Oncol       Date:  2012-05-10       Impact factor: 5.650

9.  Kank regulates RhoA-dependent formation of actin stress fibers and cell migration via 14-3-3 in PI3K-Akt signaling.

Authors:  Naoto Kakinuma; Badal Chandra Roy; Yun Zhu; Yong Wang; Ryoiti Kiyama
Journal:  J Cell Biol       Date:  2008-05-05       Impact factor: 10.539

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.